Last reviewed · How we verify
Aldocorten (ALDOSTERONE)
Aldocorten, a marketed aldosterone product, competes in the hormone imbalance symptoms market with a key composition patent expiring in 2028. Its mechanism of action through the mineralocorticoid receptor provides a strong regulatory effect on sodium and potassium levels, distinguishing it from off-patent competitors like fludrocortisone acetate. The primary risk lies in the potential increase in generic competition post-2028, which could erode market share and revenue.
At a glance
| Generic name | ALDOSTERONE |
|---|---|
| Drug class | Gonadotropin [EPC] |
| Target | Corticosteroid-binding globulin, Sex hormone-binding globulin, Mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Hormone imbalance symptoms
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (PHASE3)
- Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin (PHASE2)
- HEART: Pilot Randomized Controlled Trial (PHASE1,PHASE2)
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) (PHASE3)
- Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension (NA)
- The ENCHANTMENT HIV Study (PHASE2)
- Baroreflex Activation Therapy for Heart Failure (NA)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aldocorten CI brief — competitive landscape report
- Aldocorten updates RSS · CI watch RSS